Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...

Diabetes and obesity have emerged as major global health concerns. Glucagon-like peptide-1 (GLP-1), a natural incretin hormone, stimulates insulin production and suppresses glucagon secretion to ...